ReviewCancer medicine2026
The Immune Landscape of Acral Melanoma: From Basic to Clinical.
Review in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel 1H-Indole-3-carboxamide Derivatives as CDK4 Inhibitors for Treating Cancer.ACS medicinal chemistry letters · 2026Article
- Novel Compounds as CDK4 Inhibitors for Treating Breast Cancer.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
aimThis review examines the mechanisms driving immunotherapy resistance in AM, summarizes current clinical advances in combination regimens, and explores future therapeutic directions.
methodsA narrative review of recent literature was undertaken, encompassing studies on resistance mechanisms and clinical trials investigating novel ICI-based combination therapies for AM.
resultsAM exhibits distinct immunosuppressive microenvironment characterized by low tumor mutational burden, reduced CD8+ T-cell infiltration, enrichment of regulatory T cells, and specific genetic alterations. Emerging clinical data demonstrate that combination regimens-particularly dual ICIs (anti-PD-1 plus anti-CTLA-4) and ICI combinations with anti-angiogenic agents or chemotherapy-have shown promising efficacy, with some achieving superior response rates in AM patients. DISCUSSION: Understanding resistance mechanisms is critical for identifying novel therapeutic targets and optimizing personalized strategies. Current evidence suggests combination therapies may overcome resistance and improve outcomes, though optimal regimens and sequencing require further investigation.
conclusionContinued research into innovative combination approaches and predictive biomarkers is urgently needed to improve survival in AM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.